Solan Headlines

Cutaneous Lupus Erythematosus Emerging drugs and Key Players | DelveInsight

 Breaking News
  • No posts were found

Cutaneous Lupus Erythematosus Emerging drugs and Key Players | DelveInsight

August 13
14:24 2020
Cutaneous Lupus Erythematosus Emerging drugs and Key Players | DelveInsight

DelveInsight Business Research LLP
“Cutaneous Lupus Erythematosus (CLE) Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Cutaneous Lupus Erythematosus (CLE) market. A detailed picture of the Cutaneous Lupus Erythematosus (CLE) pipeline landscape is provided, which includes the disease overview and Cutaneous Lupus Erythematosus (CLE) treatment guidelines.

Cutaneous Lupus Erythematosus is a chronic, autoimmune disease affecting the skin, which belongs to the family of lupus erythematosus where the symptoms are restricted to the skin.

The available therapeutics options in Cutaneous Lupus Erythematosus treatment Landscape aim to reduce complications arising from Lupus Erythematosus.

Cutaneous Lupus Erythematosus Emerging Drugs

  1. BIIB059: Biogen
  2. Etanercept: Pfizer
  3. Filgotinib: Galapagos NV /Gilead Sciences
  4. GS-9876: Gilead Sciences
  5. Delgocitinib: LEO Pharma/ Japan Tobacco
  6. VIB7734: VIELABIO


BIIB059 (Biogen) is an investigational, humanized monoclonal antibody that acts as a BDCA2 inhibitor. BDCA2 is uniquely expressed on the surface of human pDCs (plasmacytoid dendritic cells) that synthesize large amounts of interferon. BIIB059 binding to BDCA2 results in its rapid internalization from the cell surface of human pDCs and the subsequent inhibition of IFN-I (all subtypes), cytokine, and chemokine production by pDCs. Biogen is conducting a Phase II clinical trial for the treatment of active Cutaneous Lupus Erythematosus and Systemic Lupus Erythematosus.

Etanercept is a dimeric, soluble form of a fully human tumor necrosis factor (TNF) receptor that can bind TNF molecules and inhibits binding of TNF-α and TNF-β to cell surface TNFRs, rendering TNF are biologically inactive. Its clinical efficacy and safety profile are established as disease-modifying agent for arthritis. The systemic administration of TNF blockers has been associated with the induction of pathogenic autoantibodies that may render SLE worse or progression from DLE only to SLE. Administering a TNF blocker, Etanercept using the intra-dermal route will provide local concentration to neutralize TNF in tissue while minimizes the effect to systemic immunity. Currently, Pfizer has completed Phase II clinical trial for the treatment of Discoid Lupus Erythematosus.

Along with the above-proven candidates, various other potential therapies are also being developed by big pharmaceutical companies for this rare indication, such as Filgotinib (Galapagos NV /Gilead Sciences), VIB7734 (Viela Bio), Delgocitinib (LEO Pharma), GS-9876 (Gilead Sciences), Secukinumab (Novartis), Tofacitinib (Pfizer) and others.

Overall, the increasing research in this condition along with upcoming novel therapies will fuel the market during the forecast period, 2020-2030.


Scope of the report

  • The Cutaneous Lupus Erythematosus (CLE) report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Cutaneous Lupus Erythematosus (CLE) across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Cutaneous Lupus Erythematosus (CLE) therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Cutaneous Lupus Erythematosus (CLE) research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Cutaneous Lupus Erythematosus (CLE).


Request for sample pages

Table of contents

1. Report Introduction

2. Cutaneous Lupus Erythematosus (CLE) 

2.1. Overview

2.2. History 

2.3. Cutaneous Lupus Erythematosus (CLE) Symptoms

2.4. Causes


2.6. Cutaneous Lupus Erythematosus (CLE) Diagnosis 

2.6.1. Diagnostic Guidelines

3. Cutaneous Lupus Erythematosus (CLE) Current Treatment Patterns

3.1. Cutaneous Lupus Erythematosus (CLE) Treatment Guidelines

4. Cutaneous Lupus Erythematosus (CLE) – DelveInsight’s Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Cutaneous Lupus Erythematosus (CLE) companies collaborations, Licensing, Acquisition -Deal Value Trends Assessment Summary

4.1.2. Cutaneous Lupus Erythematosus (CLE) Collaboration Deals Company-Company Collaborations (Licensing / Partnering) Analysis Company-University Collaborations (Licensing / Partnering) Analysis Cutaneous Lupus Erythematosus (CLE) Acquisition Analysis

5. Therapeutic Assessment

5.1. Clinical Assessment of Pipeline Drugs 

5.1.1. Assessment by Phase of Development

5.1.2. Assessment by Product Type (Mono / Combination) Assessment by Stage and Product Type

5.1.3. Assessment by Route of Administration Assessment by Stage and Route of Administration

5.1.4. Assessment by Molecule Type Assessment by Stage and Molecule Type

5.1.5. Assessment by MOA Assessment by Stage and MOA

5.1.6. Assessment by Target Assessment by Stage and Target

6. Cutaneous Lupus Erythematosus (CLE) Late Stage Products (Phase-III)

7. Cutaneous Lupus Erythematosus (CLE) Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Cutaneous Lupus Erythematosus (CLE) Discontinued Products

13. Cutaneous Lupus Erythematosus (CLE) Product Profiles

13.1. Drug Name: Company 

13.1.1. Product Description Product Overview Mechanism of action

13.1.2. Research and Development Clinical Studies

13.1.3. Product Development Activities Collaboration Agreements Acquisition Patent Detail

13.1.4. Tabulated Product Summary General Description Table

Detailed information in the report

14. Cutaneous Lupus Erythematosus (CLE) Key Companies

15. Cutaneous Lupus Erythematosus (CLE) Key Products

16. Dormant and Discontinued Products

16.1. Dormant Products

16.1.1. Reasons for being dormant

16.2. Discontinued Products 

16.2.1. Reasons for the discontinuation

17. Cutaneous Lupus Erythematosus (CLE) Unmet Needs

18. Cutaneous Lupus Erythematosus (CLE) Future Perspectives

19. Cutaneous Lupus Erythematosus (CLE) Analyst Review  

20. Appendix

21. Report Methodology

21.1. Secondary Research

21.2. Expert Panel Validation

Media Contact
Company Name: DelveInsight
Contact Person: Priya Maurya
Email: Send Email
Phone: +919650213330
City: Albany
State: New York
Country: United States

Related Articles